Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday 13, 2025. Robert A.

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $264.21 which represents a slight increase of $2.15 or 0.82% from the prior close of $262.06. The stock opened at $261.97 and touched a ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Amid a roller-coaster end to 2024 for the stock market, dividend-paying stocks continued to lag the broader market. However, ...

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of ...

The Lown Institute, an independent healthcare think tank, went about looking at some of the worst healthcare horror stories ...

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.